Aclaris Therapeutics

ACRS Rare disease Lead: Phase 2 5 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Catalyst timeline

bosakitug Ph2 topline2H 2026bosakitug Ph2 topline, 2H 2026, major
ATI-9494 ITK IND filing2H 2026ATI-9494 ITK IND filing, 2H 2026, notable
ATI-052 Ph1 topline4Q 2026ATI-052 Ph1 topline, 4Q 2026, major
bosakitug topline4Q 2026bosakitug topline, 4Q 2026, major
ATI-9494 IND filing4Q 2026ATI-9494 IND filing, 4Q 2026, notable
ATI-2138 Ph2b start4Q 2026ATI-2138 Ph2b start, 4Q 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

bosakitug

ATI-045

Protein Target: TSLP

Atopic Dermatitis Phase 2 subcutaneous Biosion NCT07011706

ATI-2138

Small Molecule Target: ITK, JAK3

Atopic Dermatitis Phase 2 oral NCT06585202

ATI-052

Protein Target: TSLP, IL-4Ra, IL-4Rα

Atopic Dermatitis Phase 1 subcutaneous Biosion
Asthma Phase 1 subcutaneous Biosion
Eosinophilic Esophagitis

lepzacitinib

ATI-1777

Small Molecule Target: JAK1, JAK3

Atopic Dermatitis Phase 2 topical Pediatrix Therapeutics NCT04598269

ATI-9494

Small Molecule Target: ITK, TXK

Undisclosed indication Preclinical oral

modzatinib

ATI-2138

Small Molecule Target: ITK, JAK3

Lichen Planus Phase 2 oral

Technology platforms

KINect

Proprietary kinase inhibitor drug discovery platform leveraging a chemical library of covalent kinase inhibitors, structure-based drug design, and custom kinase assays. Mechanisms include reversible/irreversible covalent inhibitors, molecular glues, tissue-specific inhibitors, and targeted protein degraders. Focus: chronic inflammation and autoimmune diseases.

Biotech Distilled coverage (5)

2026-08-07 UPDATE: Aclaris Therapeutics (ACRS) - The ATM Gets a Bigger Tank 🔒 Paid
2026-05-08 UPDATE: Aclaris Therapeutics (ACRS) - The Quiet ATM 🔒 Paid
2026-04-29 UPDATE: Aclaris Therapeutics (ACRS) - The Bispecific Delivered 🔒 Paid
2026-03-28 UPDATE: Aclaris Therapeutics (ACRS) - Unpacking The Phase 2a Data for ATI-2138 🔒 Paid
2026-03-24 Aclaris Therapeutics (ACRS) - Scientific Deep Dive for Bosakitug, ATI-052, and Other Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.